Association of the inflammatory marker suPAR with chronic pruritus of unknown origin – data from the SOMA.PRU study - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Link Between suPAR Inflammatory Marker and Chronic Pruritus of Unidentified Cause: Insights from the SOMA.PRU Study

  • By

  • Stefan M. Kahnert

  • Lara Jürgens

  • Leonie Dreher

  • Christian Schmidt-Lauber

  • Ansgar Koechel

  • Gina L. Frank

  • Tobias B. Huber

  • Meike Shedden-Mora

  • Sonja Ständer

  • Markus Ramm

  • Gudrun Schneider

  • Rupert Conrad

  • June 16, 2026

Share

Clinical Scorecard: Link Between suPAR Inflammatory Marker and Chronic Pruritus of Unidentified Cause: Insights from the SOMA.PRU Study

At a Glance

CategoryDetail
ConditionChronic Pruritus of Unknown Origin (CPUO)
Key MechanismsChronic systemic inflammation as a potential contributor to pruritus
Target PopulationAdults with chronic pruritus lasting ≥ 6 weeks
Care SettingDermatology outpatient department

Key Highlights

  • CPUO patients exhibited the highest suPAR levels compared to controls and cAD patients.
  • Higher baseline suPAR levels in CPUO correlated with increased pruritus intensity at follow-up.
  • Chronic pruritus affects 15% to 20% of the general population, with CPUO affecting 6-15% of pruritus patients.

Guideline-Based Recommendations

Diagnosis

  • Assess pruritus intensity using a numeric rating scale (NRS, range 0–10).
  • Differentiate between chronic pruritus of known and unknown origin.

Management

  • Consider systemic inflammation as a factor in chronic pruritus management.

Monitoring & Follow-up

  • Monitor suPAR levels as a potential biomarker for chronic inflammation in pruritus patients.

Risks

  • Chronic pruritus can significantly reduce quality of life.

Patient & Prescribing Data

Adults with chronic pruritus, including those with chronic atopic dermatitis and CPUO.

suPAR may serve as a biomarker for assessing the severity and progression of pruritus.

Clinical Best Practices

  • Incorporate assessment of systemic inflammation in the evaluation of chronic pruritus.
  • Utilize suPAR levels to inform treatment decisions and monitor disease progression.

Related Resources & Content

Original Source(s)

Association of the inflammatory marker suPAR with chronic pruritus of unknown origin – data from the SOMA.PRU study

  • by Stefan M. Kahnert, Lara Jürgens, Leonie Dreher, Christian Schmidt-Lauber, Ansgar Koechel, Gina L. Frank, Tobias B. Huber, Meike Shedden-Mora, Sonja Ständer, Markus Ramm, Gudrun Schneider, Rupert Conrad

  • June 16, 2026

Related Content

Comments on Dermatologists’ TikTok Videos on Atopic Dermatitis: Content Analysis

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

Mental Health May Impact Dermatologic Quality of Life

Poorer dermatology-related quality of life was associated with greater mental health issues, while habitual probiotic intake showed no measurable relationship with these outcomes.